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ugene, Oregon; and Orlando, Florida
OBJECTIVES We sought to evaluate the relationship between angiographic late loss and clinical outcomes
in the drug-eluting stent era.
BACKGROUND The interrelationship between angiographic late loss, binary restenosis, and clinical recurrence
(target lesion revascularization [TLR]) after coronary stent implantation has been incom-
pletely evaluated.
METHODS Using the angiographic substudy of the TAXUS-IV trial, in which 1,314 patients with de
novo coronary lesions were randomized to either the paclitaxel-eluting TAXUS stent or to its
bare-metal equivalent, we defined the relationship between in-stent and analysis segment late
loss, the shape of the late loss histogram (variance and skewedness), and nine-month TLR.
RESULTS Late loss by several measures was closely related to TLR (area under the receiver-operator
curve 0.90). For individual vessels of the size in this study (2.8  0.5 mm), the likelihood
of TLR did not exceed 5% until analysis segment late loss was 0.5 mm, and did not exceed
10% until late loss was 0.65 mm. At greater late losses, the late loss TLR relationship was
steep and nearly linear. For the overall patient cohort, the rate of TLR was related, however,
not only to median late loss, but also to measures of its statistical distribution (TLR increased
with lack of homogeneous biologic response [greater variance and greater right skewedness]).
Similar relationships held for late loss measured within the confines of the stent itself.
CONCLUSIONS Coronary stents result in large lumens with “room” to accommodate up to 0.5 to 0.65 mm
of tissue (angiographic analysis segment late loss) before the likelihood of clinical restenosis
(TLR) exceeds 5% to 10%. These data have important implications toward understanding the
absolute and relative efficacy of drug-eluting stents. (J Am Coll Cardiol 2005;45:1193–200)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.063© 2005 by the American College of Cardiology Foundation
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dhe aim of drug-eluting stents is to provide local vascular
rug delivery to reduce neointimal responses that lead to
estenosis and the need for further revascularization. Com-
ared with bare-metal stents, polymer-based elution of
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ndianapolis, Indiana; #Elyria Memorial Hospital, Elyria, Ohio; **WakeMed, Ra-
eigh, North Carolina; ††Washington Adventist Hospital, Tacoma Park,
aryland; ‡‡St. Joseph’s Hospital, Syracuse, New York; §§Sacred Heart Medical
enter, Eugene, Oregon;  Florida Hospital, Orlando, Florida; ¶¶Columbia Uni-
ersity Medical Center, New York, New York; and the ##Cardiovascular Research
oundation, New York, New York. Drs. Ellis and Popma receive research support
rom Boston Scientific; Drs. Ellis, Stone, and Hermiller are consultants for Boston
cientific; and Dr. Koglin is an employee of Boston Scientific. The data reside with,
ut were also reviewed externally from, Boston Scientific. Dr. Ellis feels as an
nvestigator in the filed, he has “conflict” with all major U.S. stent manufacturers, and
ence feels “conflicted” in a “balanced” fashion.c
Manuscript received June 28, 2004; revised manuscript received November 1, 2004,
ccepted November 15, 2004.irolimus and paclitaxel significantly reduce the need for
arget lesion revascularization (TLR) (1,2). For bare-metal
tents, the restenotic process is heterogeneous, occurring
ocally or diffusely within the stent(s), including the edges
3). In contrast, when restenosis occurs after placement of
rug-eluting stents, the pattern is typically focal in nature
1,2). Quantitative angiographic algorithms and analysis
ay be utilized to identify the most narrowed lumen or the
inimum lumen diameter (MLD) to reflect the severity of
estenosis. The MLD is then used to derive most common
ngiographic indexes (binary restenosis rates, % diameter
tenosis, late loss, and late loss index) reflecting the process
f restenosis (4).
Late loss, defined as the difference in millimeters between
he MLD at the completion of the procedure and at
ngiographic follow-up, is commonly used to measure the
egree of accumulation of tissue (4). Late loss can be
alculated based on measurements within the stent, at its
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Late Loss and TLR April 19, 2005:1193–200dges, or across the entire analysis segment, as has been
one historically. Some have speculated that in-stent late
oss might serve as a useful measure of biological activity of
rug-eluting stents, with the implication clearly being that
less is better” (5,6). In the era of drug-eluting stents, the
ignificance and relationship of the traditional angiographic
ndexes of restenosis, especially late loss, to clinical out-
omes has yet to be defined.
When comparing results from the SIRIUS and
AXUS-IV trials (1,2), both drug-eluting stent systems
rovide significant reductions in in-stent neointimal hyper-
lasia compared to bare-metal stents, translating into a
reatly reduced and generally similar need for repeat inter-
ention (nine-month TLR rates of 4.1% and 3.0%, respec-
ively) in analogous patient and lesion populations. One
ajor difference between the Cypher (Cordis Corp., Mi-
mi, Florida) and TAXUS (Boston Scientific Corp., Natick,
assachusetts) stent systems is the absolute amount of
ngiographic late loss seen at late follow-up (the same
ngiographic core laboratory and analysis technique was
tilized in both studies). For the Cypher stent, in-stent late
oss was 0.17  0.44 mm compared with 1.00  0.70 mm
or bare-metal control stents (relative reduction of 83%).
or the TAXUS stent, the late loss was 0.39 0.50 mm for
he slow-release, polymer-based paclitaxel-eluting stent
ompared to 0.92 0.58 mm for the EXPRESS bare-metal
ontrol (Boston Scientific Corp.) (relative reduction of
8%). The degree of late loss over the entire analysis
egment, however, was similar between the Cypher and
AXUS stents (0.24  0.47 mm and 0.23  0.44 mm,
espectively). These contrasts have raised questions about
he utility of late loss as an index of clinical restenosis in the
rug-eluting stent era. The objective of this substudy was,
herefore, to examine the relationship between late loss and
LR.
ETHODS
tudy population and protocol. The TAXUS-IV trial
andomized patients to receive either the polymer-based,
aclitaxel-eluting TAXUS stent or to a bare-metal equiva-
ent. Patients 18 years of age with stable or unstable
ngina or provocable ischemia undergoing stenting of a
ingle de novo lesion in a native coronary artery were
onsidered for enrollment. Angiographic eligibility for in-
lusion required a target lesion with visual reference vessel
iameter2.5 to3.75 mm and lesion length 10 to 28 mm
overable by a single study stent. Clinical and angiographic
xclusion criteria have been described (2). The institutional
Abbreviations and Acronyms
MLD minimum lumen diameter
QCA quantitative coronary angiography
TLR  target lesion revascularizationeview board at each participating center approved the Ctudy, and consecutive, eligible patients signed informed,
ritten consent; 559 of the 732 patients (76.4%) pre-
elected for routine angiographic follow-up returned for
estudy. Additionally, 150 patients had angiographic
ollow-up one to nine months after stent placement for
linical indications. The latter group’s data were added in
ome analyses to increase the number of events to be
tudied.
andomization and stent implantation. Telephone ran-
omization was performed before pre-dilatation, stratified
y the presence of medically treated diabetes and vessel size
3.0 or 3.0 mm). Patients were equally assigned in
ouble-blind fashion to treatment with either the slow
ate-release, polymer-based, paclitaxel-eluting TAXUS
tent or a visually indistinguishable bare-metal EXPRESS
tent. Unfractionated heparin was administered per stan-
ard practice, and glycoprotein IIb/IIIa inhibitor use was at
perator discretion. After mandatory pre-dilatation, an
ppropriate-sized stent (approximately 2 to 4 mm longer
han the lesion, with a stent-to-distal reference vessel
iameter ratio of 1 to 1.1:1) was implanted at 12 atm.
tents were available in lengths of 16, 24, and 32 mm, and
n diameters of 2.5, 3.0, and 3.5 mm. Additional study
tents were permitted for edge dissections greater than or
qual to type B or otherwise suboptimal results, and
ost-dilatation was at operator discretion. Clinical
ollow-up was scheduled at one, four, and nine months, and
early thereafter for five years. Angiographic follow-up was
re-specified in a prospectively identified subgroup of 732
atients at nine months (2).
nd points and definitions. Target lesion revasculariza-
ion was defined as either repeat percutaneous or surgical
evascularization for a lesion anywhere within the stent or
he 5-mm borders proximal or distal to the stent. Target
esion revascularization was considered to be ischemia-
riven if the target lesion diameter stenosis was 50% by
uantitative analysis with either electrocardiographic
hanges at rest or a positive functional study in the distri-
ution of the target lesion, or 70% with recurrent symp-
oms only. If an adverse event could not be conclusively
ttributed to a non-target lesion, then the event was
onsidered a target-related event.
As previously described, the primary end point of the
AXUS-IV trial was TVR at nine months (2), defined as
evascularization due to either restenosis in the target lesion,
r to a new remote lesion elsewhere in the target vessel or its
ranches. For the present analysis, however, TLR was used
s the principal clinical analysis end point, as angiographic
estenosis after stent implantation (either within the stent or
t its margins) is most directly correlated with TLR.
ngiographic methods. After administration of intracoro-
ary nitroglycerin, standard angiographic image acquisition
f the coronary stenosis was performed using at least two
ngiographic projections that were repeated at the end of
he procedure and at the time of follow-up angiography.
ineangiograms were then forwarded to the Brigham and
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April 19, 2005:1193–200 Late Loss and TLRomen’s Hospital Angiographic Core Laboratory for re-
iew by observers blinded to the treatment assignment.
aseline, postprocedural, and follow-up qualitative mor-
hologic characteristics were characterized using standard
riteria (7–9). Lesion length was defined as the axial extent
f the lesion that contained a shoulder-to-shoulder lumen
eduction by 20% or more (10).
Using the contrast-filled injection catheter as the calibration
ource, quantitative coronary angiographic (QCA) analysis was
erformed using a validated automated edge detection algo-
ithm (Medis CMS, Leiden, the Netherlands) (11). Projec-
ions for image analysis were identified using views that
emonstrated the stenosis in an unforeshortened view,
inimized the degree of vessel overlap, and displayed the
tenosis in its “sharpest and tightest” view. A 5-mm seg-
ent of reference diameter proximal and distal to the
tenosis was used to calculate the average reference vessel
iameter; side branches and other anatomic landmarks were
sed to identify and maintain the consistency of the mea-
urement length during the follow-up period. Minimum
umen diameters were measured at these same time points
ithin the stent (in-stent analysis) and within the 5-mm
roximal and distal edges of the stent. Total occlusions were
ssigned an MLD  0 mm and a 100% diameter stenosis.
Angiographic follow-up was performed nine months
fter the index procedure, or earlier in the event of recurrent
able 1. Selected Patient Characteristics and Outcomes
Patients Not in
Angiographic
Substudy
(n  582)
p
Val
linical
Acute coronary syndrome (%) 32.3 0.2
Age (yrs) 62.1  11.3 0.5
Diabetes mellitus–insulin (%) 6.9 0.2
Diabetes mellitus–requiring medication (%) 22.2 0.1
Hyperlipidemia (%) 65.8 0.7
Hypertension (%) 68.7 0.4
Male gender (%) 72.9 0.5
Renal dysfunction (%) 3.6 0.6
Smoking, current (%) 22.2 0.7
aseline angiography and treatment
Reference vessel diameter (mm) 2.72  0.48 0.0
Lesion length (mm) 12.1  5.1 0.0
% diameter stenosis 66.1  10.6 0.9
Stent/lesion length ratio, mean  SD
(20th/50th/75th percentile)
1.81  0.83
(1.32/1.61/2.08)
0.3
ine-month outcomes
Binary restenosis, in-stent (%) 25.3 (n  150) 0.0
Binary restenosis, in-segment (%) 28.0 (n  150) 0.0
Late loss, in-stent (mm) 0.72  0.72
(n  150)
0.1
Late loss, in-segment (mm) 0.50  0.63
(n  150)
0.0
Target lesion revascularization (%) 7.2 1.0
Target vessel revascularization (%) 8.2 1.0
Cardiac death (%) 1.0 0.6ymptoms. Binary angiographic restenosis was defined as a collow-up diameter stenosis 50%. Acute gain was defined
s the MLD immediately after the procedure minus the
LD before the procedure, and late loss was defined as the
LD immediately after the procedure minus the MLD at
ollow-up. For the purposes of this analyses, late loss was
alculated in each of three ways: 1) within the stent itself; 2)
ithin the analysis segment itself considering the MLD
nywhere within the analysis segment at the conclusion of
he procedure and at follow-up; and 3) within the analysis
egment itself, but separately considering the stented seg-
ent, proximal and distal edges and taking the maximum
hange in MLD within those three segments and applying
t to this segment as a whole (maximal regional late loss) to
etter reflect local dimensional changes.
tatistical methods. Categorical variables were compared
y the Fisher exact test. Continuous variables are presented
s mean  1 SD or median with 25% and 75% interquartile
anges, and were compared by Student t test. Late loss data
y treatment group were displayed as histograms and
nalyzed for variance, or the dispersion of the distribution of
ata around the mean value, and skewedness or the asym-
etry of the data distribution and for its relation to TLR.
umulative frequency distribution curves for each of the
hree measures of late loss (in-stent, in-segment, and
aximal regional late loss) was plotted against TLR, and
he goodness of correlation assessed using receiver operator
Patients in
Angiographic
Substudy
(Intention-to-Treat)
(n  732)
Patients in
Angiographic
Substudy With
Follow-Up
(n  599)
p
Value
Patients in
Angiographic
Substudy With
No Follow-Up
(n  173)
35.8 33.8 0.05 42.2
62.6  10.9 62.3  10.8 0.10 63.8  11.0
8.9 8.4 0.44 10.4
25.8 24.3 0.11 30.6
64.9 64.6 0.79 65.9
70.6 69.8 0.39 73.4
71.4 72.6 0.21 67.6
4.2 3.8 0.28 5.8
21.4 20.0 0.11 26.0
2.78  0.48 2.78  0.48 0.79 2.77  0.45
14.4  6.9 13.9  6.6 0.01 16.3  7.3
66.1  10.8 65.6  10.8 0.02 67.7  10.5
1.86  0.99
(1.28/1.58/2.11)
1.84  0.96
(1.28/1.57/2.07)
0.32 1.93  1.11
(1.28/1.60/2.17)
14.5 (n  557) 14.5 NA NA
16.8 (n  558) 16.8 NA NA
0.64  60
(n  557)
0.64  0.60 NA NA
0.41  0.54
(n  558)
0.41  0.54 NA NA
7.1 8.9 0.001 1.2
8.3 10.9 0.001 1.2
1.4 0.7 0.014 3.5ue
0
2
2
4
7
7
8
7
9
5
1
9
6
03
03
16
99
00
00urve analyses and the c-statistic. Separate analyses were
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Late Loss and TLR April 19, 2005:1193–200hen performed dividing the population by reference vessel
ize 2.5 mm, 2.5 to 3.0 mm, and 3.0 mm. To assess the
LR implications of greater and lesser heterogeneity and
reater right skewedness of late loss than was actually
resent in the TAXUS group, simulation exercises were
erformed assuming: 1) the same mean late loss with a
aussian distribution, but with 50%, 75%, 125%, or 150%
f the observed variance of late loss; and 2) skewed distri-
utions, with the same mean late loss but kurtoses of 0.37
nd 0.41 representing greater right skewedness; 1,000 sim-
lations were performed for each estimate. Finally, because
ot all patients with binary restenosis had TLR, similar
nalyses were performed with binary restenosis as the end
oint.
ESULTS
aseline demographic and angiographic findings. Se-
ected patient characteristics and outcomes are shown for
atients with and without angiographic follow-up in Table
, and for patients randomized to the paclitaxel-eluting or
ontrol stents within the angiographic follow-up group in
able 2. Patients scheduled for angiographic follow-up
iffered from those not prescheduled only with regard to
esion length (given that angiographic follow-up was man-
ated in all patients with 32-mm stent implantation) (6) and
ith respect to binary restenosis (higher in the non-
rescheduled group due to the ascertainment bias engen-
able 2. Comparison of TAXUS Versus Control for Patients Wi
T
(n
linical
Acute coronary syndrome (%)
Age (yrs) 63.0
Diabetes mellitus–insulin (%)
Diabetes mellitus–requiring medication (%)
Hyperlipidemia (%)
Hypertension (%)
Male gender (%)
Renal dysfunction (%)
Smoking current (%)
aseline angiography and treatment
Reference vessel diameter (mm) 2.76
Lesion length (mm) 13.8
% diameter stenosis 65.9
Stent/lesion length ratio* 1.83
(20th/50th/75th percentile) (1.25/
ine-month outcomes
Binary restenosis, in-stent (%)
Binary restenosis, in-segment (%)
Late loss, in-stent (mm)* 0.39
(0.04/
Late loss, in-segment (mm)* 0.23
(0.04
Target lesion revascularization (%)
Target vessel revascularization (%)
Mean  SD.ered by the propensity of patients with symptoms to return aor angiography). Patients prescheduled for angiographic
ollow-up returning for study had a mean reference vessel
iameter of 2.78  0.48 mm and lesion length 13.9 
.6 mm, with no significant differences between patients
andomized to paclitaxel-eluting or control with respect to
hese or other key baseline variables. Compared to patients
andomized to a bare-metal stent, paclitaxel-eluting ran-
omized patients had significantly lower analysis segment
inary restenosis rates (7.9% vs. 26.6%, p  0.0001) and
LR rates (3.8% vs. 14.6%, p  0.0001). Only two and
hree patients, respectively, had total stent occlusion at
ollow-up.
istribution of late loss. Distributions of late loss for the
aclitaxel-eluting and control groups are shown in Figures
A to 1C. Mean analysis segment late loss in paclitaxel-
luting group compared to the control group was signifi-
antly less (0.23  0.44 vs. 0.61  0.57, p  0.0001), less
eterogeneous by variance measurement (0.192 vs. 0.329),
ut less symmetrically distributed (right skewedness 1.54 vs.
.71). Data for in-stent and maximal regional late loss were
imilar.
umulative frequency distribution curves. Patient
ounts for those with and without TLR by 0.2-mm late
oss increments are shown in Figures 2A to 2C. The
esultant cumulative frequency distribution curves show-
ng TLR rates as a function of late loss are shown for late
oss calculated within the in-stent segment (Fig. 3A),
ngiographic Follow-Up
2) p Value
Control
(n  267)
0.59 32.6
1.1 0.09 61.5  10.4
0.76 7.9
0.20 21.7
1.00 64.4
0.03 65.2
0.85 73.0
1.00 3.7
0.29 18.0
.49 0.27 2.80  0.48
.5 0.93 13.9  6.8
0.7 0.39 65.2  10.9
.91 0.88 1.84  1.01
2.05) (1.29/1.59/2.09)
0.0001 24.4
0.0001 26.6
.50 0.0001 0.92  0.58
0.60) (0.52/0.88/1.26)
.44 0.0001 0.61  0.57
/0.41) (0.20/0.54/0.91)
0.0001 14.6
0.0005 15.4th A
AXUS
 29
34.9
 1
8.9
26.7
64.7
74.0
72.3
3.8
21.9
 0
 6
 1
 0
1.55/
5.5
7.9
 0
0.34/
 0
/0.15
3.8
6.2nalysis segment including the stent and the regions
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April 19, 2005:1193–200 Late Loss and TLRxtending 5 mm from the stent margin (Fig. 3B) and
aximal regional late loss (Fig. 3C). As the late loss-
LR curves for the patients treated with paclitaxel-
luting and control stents were very similar, combined
ata were used for subsequent analyses. C-statistics for
he in-stent, analysis segment, and maximal regional late
oss TLR curves were 0.918, 0.925, and 0.934, respec-
ively (p  NS for between group comparison). Hosmer
nd Lemeshow TLR goodness of fit statistics were 5.033
p  0.75), 8.093 (p  0.42), and 7.245 (p  0.51),
espectively. For binary restenosis goodness of fit statis-
ics were less consistently good: 48.312 (p  0.0001),
.167 (p  0.62), and 20.334 (p  0.009), respectively.
he inflection point and threshold for 5% and 10%
isk of TLR varied across the methodologies, being
pproximately 0.75 and 1.0 mm, 0.5 and 0.65 mm, and
.1 and 1.2 mm for the in-stent, analysis segment, and
aximal regional late loss analyses, respectively.
Figure 4 shows cumulative frequency distribution
urves for analysis segment late loss versus TLR for
atients with reference vessel 2.5 mm, 2.5 to 3.0 mm,
igure 1. Histograms for late loss for the paclitaxel-eluting and control b
aximal regional (C) late loss definitions. Paclitaxel-eluting-treated patiennd 3.0 mm. Curves for the smaller and larger vessels dre shifted leftward 0.3 mm and rightward 0.7 mm,
espectively.
LR implications of altering the frequency distribution
f late loss in the TAXUS group. As displayed in Table 3,
reater homogeneity of the late loss response (e.g., 50% of
bserved variance) would be associated with lower rates of
LR (1.9%) than that seen with the observed variance.
onversely, greater heterogeneity of late loss response (e.g.,
50% of observed variance) would be associated with higher
ates of TLR (7.4%). Similarly, greater right skewedness of
he data distribution would be expected to be associated
ith higher rates of TLR (Table 4).
ISCUSSION
he principal findings of this late loss analysis from the
AXUS-IV trial for de novo native vessel coronary lesions
re: 1) late loss is strongly (c-statistic0.90) but not linearly
orrelated to TLR, and this correlation is preserved for both
aclitaxel-eluting and bare-metal stents, and for late loss
alculated as in-stent or either of the analysis segment
etal EXPRESS stent groups for in-stent (A), analysis segment (B), and
d less, but more heterogeneously distributed, late loss.are-m
ts haefinitions (2). Individual patients have a very low proba-
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Late Loss and TLR April 19, 2005:1193–200ility of TLR (5% to 10%) until analysis segment late loss
xceeds 0.5 to 0.65 mm (or in-stent late loss exceeds 0.75 to
.0 mm), and the probability of TLR exceeds 50% only
hen analysis segment and in-stent late loss exceeds
igure 2. Patient count data for those with and without target lesion
evascularization (TLR), dividing late loss into 0.2-mm increments: (A)
n-stent, (B) analysis segment, (C) maximal regional late loss..25 mm and 1.5 mm, respectively (3). In addition to the tbsolute amount of late loss, the risk of TLR is also related
o the homogeneity of late loss effect (the lower the variance
nd skewedness, the lower the TLR rate).
ate loss clinical implications. The clinical translation of
igure 3. Cumulative frequency distribution curves for (A) in-stent,
B) in-segment, (C) maximal regional late loss for the combined angio-
raphic populations versus target lesion revascularization (TLR). Prob 
robability.his finding is that the large lumens that result after coronary
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April 19, 2005:1193–200 Late Loss and TLRtent implantation in vessels of the size studied (mean 2.8
.5 mm) allow “room” to accommodate a mean late loss of
p to approximately 0.75 to 1.0 mm within the stent,
roviding that there is a homogeneous effect across the
ajor subpopulations of patients. When the entire analysis
egment is considered, any degree of late loss 0.5 mm is
ufficient to result in TLR rates below 5%. For smaller
eference vessel dimensions, the amount of “room” to
ccommodate restenotic tissue diminishes, such that for the
roup with diameter 2.5 (mean 2.22  0.20 mm), the
robability of TLR exceeds 10% when analysis segment late
oss is 0.5 mm, rather than 0.6 to 0.7 mm for the entire
roup. When the TLR threshold is lowered to 5% for small
essels (2.5 mm), a late lumen loss of 0.3 to 0.4 mm or
elow is acceptable.
ate loss findings in paclitaxel-eluting stents. For the
aclitaxel-eluting stent group as a whole, the likelihood of
LR is directly, but not linearly, related to late loss and
ncreases with greater heterogeneity of effect (more vari-
nce) and with greater right skewedness of the late loss
istribution curve compared with the bare-metal stent (2).
hese data have important implications for the requisite
erformance of drug-eluting stents. A mean analysis seg-
ent late loss of 0.5 mm (or in-stent late loss of 0.75 mm)
fter drug-eluting stent implantation is adequate to achieve
LR rates 5%. Greater reduction of late loss may not
ranslate into significantly lower TLR rates, because the
elatively flat portion of the TLR/late loss curve has been
eached. These data provide insight as to why Cypher and
AXUS stents result in similar TLR rates despite exhibit-
ng very different degrees of in-stent late loss. Moreover, the
igure 4. Cumulative frequency distribution cares for in-segment late loss
ersus target lesion revascularization (TLR) for reference vessel size 2.5,
.5 to 3.0, and 3.0 mm. Prob  probability.
able 3. Simulated Impact of Different In-Stent Late Loss
ariances on TLR in the TAXUS Stent Population
Variance (% Observed) Expected TLR (%)
50% 1.9
75% 2.6
100% 3.8
125% 5.5
150% 7.4mLR  target lesion revascularization.imilar amount of late loss in the analysis segments after
irolimus-eluting and paclitaxel-eluting stent implantation
despite different degrees of in-stent hyperplasia) contribute
o the near identical rates of TLR.
In addition, the homogeneity of response to the drug-
luting stent as a function of vessel size, lesion length,
iabetic status, and other parameters must be considered to
ompletely characterize drug-eluting stent performance. In
his regard from the present analysis, the TAXUS stent
erformed slightly better in smaller compared to larger
essels, with less absolute and relative late loss. Moreover,
are-metal stents typically have a late loss of 0.8 to 1.0 mm
12–14). The present analysis suggests that changes in
aterials or manufacturing processes that could reduce this
ate loss to the 0.5- to 0.6-mm range (a reduction of only
0.2 to 0.4 mm) would have a marked impact on reducing
estenosis even without a bioactive coating.
This study also demonstrates that when analysis segment
ate loss is0.5 mm (or when in-stent late loss is0.75
m), that the homogeneity of response (variance and skew)
ay affect TLR rates more powerfully than any further
eduction in median late loss.
ate loss findings in bare-metal stents. For bare-metal
tents, a majority of patients have late loss on the steep and
inear portion of the TLR/late loss curve, and, therefore, late
oss itself is a good measure of clinical benefit. In contrast,
or late losses in the ranges expected with drug-eluting
tents, the exact amount of late loss is an insensitive
eterminant of clinical restenosis, with homogeneity of
ffect being a more important predictor of clinical benefit.
tudy limitations. The principal limitations of this analysis
re that much of the angiographic follow-up was per protocol
ather then clinically driven, hence TLR may have been
rtificially exaggerated due to the “oculostenotic reflex” (despite
ttempts to systematically adjudicate against this) (15). Second,
he results may not be generalizable to all stent platforms or
ther types of drug-eluting stents or other lesion types. Con-
ersely, the strengths of the study lie in the large number of
atients studied, the blinded, independent QCA process, the
onsistency of the TLR late loss relationship for both the
aclitaxel-eluting stent and bare-metal stent groups, and of the
arious measures of late loss to that relationship.
linical implications. In conclusion, considering the sal-
tary scaffolding effects of stents when implanted in de novo
oronary artery stenoses, median analysis segment late loss
f up to 0.5 to 0.65 mm (or in-stent late loss of 0.75 to 1.0
able 4. Simulated Impact of Different In-Stent Late Loss
kewedness on TLR in the TAXUS Stent Population
Skewedness (Kurtosis) Expected TLR (%)
0.00 3.8
0.37 4.6
0.41 5.7
LR  target lesion revascularization.m) may be accommodated with probability of TLR 5%
t
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Late Loss and TLR April 19, 2005:1193–200o 10% provided that there is homogeneous effect across all
ubpopulations.
For the slow-release paclitaxel formulation stents, the
edian (0.15 mm) and interquartile range (0.04 to
.41 mm) values of analysis segment late loss fall far below
he threshold where the probability of TLR increases. These
ndings are important in selecting drug candidates and dose
hresholds for future drug-eluting stents where the antire-
tenotic effect needs to be balanced against adequate stent
overage consistent with a well-healed and pacified surface.
esults from future drug-eluting stent studies evaluating
ther stent platforms and drugs, as well as a broader range
f stent diameters and lengths and other lesion types, will
rovide more insight to prospectively determine the opti-
um amount of late loss combining sufficient antirestenotic
roperties and adequate healing after stent implantation.
Finally, these results potentially have important clinical
nd regulatory implications for ongoing trials in which
rug-eluting stents are compared against each other, using
ngiographic late loss as a surrogate of clinical benefit. The
resent analysis suggests that a relatively broad “delta” for
oninferiority in such studies would provide reasonable
ssurance of clinical efficacy, as long as variance of the
istribution is not excessive.
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